View in EDS

Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease.

Saved in:
Bibliographic Details
Title: Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease.
Authors: Burton J; Biogen Inc., Cambridge, MA, USA. Electronic address: Jackson.Burton@Biogen.com., Brothers HM; Biogen Inc., Cambridge, MA, USA., Hutchison RM; Biogen Inc., Cambridge, MA, USA., Murphy J; Biogen Inc., Cambridge, MA, USA., Sun T; Biogen Inc., Cambridge, MA, USA., Dent G; Biogen Inc., Cambridge, MA, USA., Curiale G; Biogen Inc., Cambridge, MA, USA., Kowalski K; Kowalski PMetrics Consulting, LLC, Naples, FL, USA.
Source: The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2025 Aug; Vol. 12 (7), pp. 100202. Date of Electronic Publication: 2025 May 24.
Publication Type: Journal Article; Clinical Trial, Phase III
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40413110
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Burton+J%22">Burton J</searchLink>; Biogen Inc., Cambridge, MA, USA. Electronic address: Jackson.Burton@Biogen.com.<br /><searchLink fieldCode="AU" term="%22Brothers+HM%22">Brothers HM</searchLink>; Biogen Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hutchison+RM%22">Hutchison RM</searchLink>; Biogen Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Murphy+J%22">Murphy J</searchLink>; Biogen Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sun+T%22">Sun T</searchLink>; Biogen Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dent+G%22">Dent G</searchLink>; Biogen Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Curiale+G%22">Curiale G</searchLink>; Biogen Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kowalski+K%22">Kowalski K</searchLink>; Kowalski PMetrics Consulting, LLC, Naples, FL, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101638820%22">The journal of prevention of Alzheimer's disease</searchLink> [J Prev Alzheimers Dis] 2025 Aug; Vol. 12 (7), pp. 100202. <i>Date of Electronic Publication: </i>2025 May 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101638820 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2426-0266 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222745807%22">22745807 </searchLink><i>NLM ISO Abbreviation: </i>J Prev Alzheimers Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40413110
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.tjpad.2025.100202
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100202
    Titles:
      – TitleFull: Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Burton J
      – PersonEntity:
          Name:
            NameFull: Brothers HM
      – PersonEntity:
          Name:
            NameFull: Hutchison RM
      – PersonEntity:
          Name:
            NameFull: Murphy J
      – PersonEntity:
          Name:
            NameFull: Sun T
      – PersonEntity:
          Name:
            NameFull: Dent G
      – PersonEntity:
          Name:
            NameFull: Curiale G
      – PersonEntity:
          Name:
            NameFull: Kowalski K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2426-0266
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The journal of prevention of Alzheimer's disease
              Type: main
ResultId 1